After a wonderful journey at Fluence Bioengineering, culminating with the acquisition by Osram to position them for global expansion, I have the pleasure to continue supporting the growth of the cannabis industry and accelerating its convergence with traditional commercial agriculture. The journey continues with exploring the tremendous financial gains for large scale cannabis producers to begin production with proprietary and exclusive tissue-cultured genetics that are ‘fingerprinted’ and pathogen-free as they embrace the journey of discovery for enhanced chemotype expression within optimized cultivation conditions. With many partners, including Catalyst and Segra, we look forward to serving our clients, the evolving consumer, and the medical community as we collaboratively uncover the benefits this plant can offer society. It’s truly an incredible time to be serving the commercial agriculture and healthcare industries!